- Home
- UHS vs BBIO Comparison
UHS vs BBIO Comparison
Compare UHS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHS
- BBIO
- Stock Information
- Founded
- UHS 1978
- BBIO 2015
- Country
- UHS United States
- BBIO United States
- Employees
- UHS N/A
- BBIO N/A
- Industry
- UHS Hospital/Nursing Management
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- UHS Health Care
- BBIO Health Care
- Exchange
- UHS Nasdaq
- BBIO Nasdaq
- Market Cap
- UHS 10.0B
- BBIO 8.8B
- IPO Year
- UHS N/A
- BBIO 2019
- Fundamental
- Price
- UHS $163.06
- BBIO $47.37
- Analyst Decision
- UHS Buy
- BBIO Strong Buy
- Analyst Count
- UHS 15
- BBIO 16
- Target Price
- UHS $222.07
- BBIO $61.50
- AVG Volume (30 Days)
- UHS 1.0M
- BBIO 2.2M
- Earning Date
- UHS 07-28-2025
- BBIO 08-05-2025
- Dividend Yield
- UHS 0.49%
- BBIO N/A
- EPS Growth
- UHS 39.27
- BBIO N/A
- EPS
- UHS 18.95
- BBIO N/A
- Revenue
- UHS $16,460,285,000.00
- BBIO $127,415,000.00
- Revenue This Year
- UHS $9.37
- BBIO $106.33
- Revenue Next Year
- UHS $5.27
- BBIO $54.30
- P/E Ratio
- UHS $8.60
- BBIO N/A
- Revenue Growth
- UHS 9.61
- BBIO N/A
- 52 Week Low
- UHS $152.33
- BBIO $21.72
- 52 Week High
- UHS $243.25
- BBIO $48.68
- Technical
- Relative Strength Index (RSI)
- UHS 40.80
- BBIO 64.99
- Support Level
- UHS $152.33
- BBIO $45.11
- Resistance Level
- UHS $169.65
- BBIO $48.07
- Average True Range (ATR)
- UHS 6.26
- BBIO 1.39
- MACD
- UHS -0.20
- BBIO -0.20
- Stochastic Oscillator
- UHS 32.84
- BBIO 68.42
About UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.